Plus Therapeutics Files 2024 10-K, Cites Key Agreements
Ticker: PSTV · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, medical-devices, contracts
TL;DR
PLUS filed 2024 10-K. Big deal: Feb 2025 securities deal & Texas cancer research contract.
AI Summary
Plus Therapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Cytori Therapeutics, Inc. and Macropore Inc., is focused on surgical and medical instruments. Key events include a securities purchase and exchange agreement on February 13, 2025, and a contract with the Cancer Prevention and Research Institute of Texas from January 1, 2024, to December 31, 2024.
Why It Matters
This filing provides investors with a comprehensive overview of Plus Therapeutics' financial health, operational performance, and strategic direction for the fiscal year 2024, including significant contractual developments.
Risk Assessment
Risk Level: medium — The company has a history of name changes and operates in the medical device sector, which can involve significant regulatory and market risks.
Key Numbers
- 2024 — Fiscal Year (Reporting period for the 10-K filing.)
- 20250331 — Filing Date (Date the 10-K was submitted to the SEC.)
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Filer
- CYTORI THERAPEUTICS, INC. (company) — Former Company Name
- MACROPORE INC (company) — Former Company Name
- 20241231 (date) — Fiscal Year End
- 20250331 (date) — Filing Date
- February 13, 2025 (date) — Securities Purchase and Exchange Agreement Date
- Cancer Prevention and Research Institute of Texas (company) — Contracting Party
FAQ
What was the primary business of Plus Therapeutics, Inc. historically?
Plus Therapeutics, Inc. was formerly known as Cytori Therapeutics, Inc. and Macropore Inc., and operates within the Surgical & Medical Instruments & Apparatus industry (SIC 3841).
When did Plus Therapeutics, Inc. file its 2024 10-K report?
The 10-K report for the fiscal year ending December 31, 2024, was filed on March 31, 2025.
What significant subsequent event occurred in February 2025?
On February 13, 2025, Plus Therapeutics, Inc. entered into a Securities Purchase and Exchange Agreement.
Did Plus Therapeutics have any contracts with Texas-based research institutions in 2024?
Yes, Plus Therapeutics had a contract with the Cancer Prevention and Research Institute of Texas for the period of January 1, 2024, to December 31, 2024.
What is the company's principal business address?
The company's business address is 4200 Marathon Blvd., Suite 200, Austin, TX 78756.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding PLUS THERAPEUTICS, INC. (PSTV).